[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Breton AL, Poulalhon N, Balme B, Thomas L, Dalle S: Primary cutaneous marginal zone lymphoma as a complication of radiation therapy: Case report and review. Dermatol Online J; 2010;16(12):6
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous marginal zone lymphoma as a complication of radiation therapy: Case report and review.
  • BACKGROUND: The occurrence of primary cutaneous B-cell lymphoma at the site of radiation therapy is exceptional.
  • We report herein the case of a primary cutaneous marginal zone lymphoma arising at the site of radiotherapy for breast cancer.
  • METHODS/RESULTS: A seventy-year-old woman was diagnosed in 2005 with an invasive ductal carcinoma of the left breast, which was treated with surgery, adjuvant chemotherapy, and radiation therapy.
  • Three years later she developed several cutaneous nodules on her left breast, followed by similar lesions on her back.
  • Histologic, immunohistochemistry, and molecular findings were consistent with the diagnosis of cutaneous marginal zone lymphoma.
  • CONCLUSIONS: To our knowledge, this is the first published case of primary cutaneous marginal zone lymphoma occurring at the site of radiotherapy.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / etiology. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Chlorambucil / administration & dosage. Combined Modality Therapy. Female. Humans. Rituximab

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21199632.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


2. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S: Non-Hodgkin lymphoma of the breast. Cancer; 2007 Jul 1;110(1):25-30
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma of the breast.
  • BACKGROUND: Primary lymphoma of the breast has been reported to have a high local and central nervous system recurrence (CNS) rate, suggesting the need for consolidation radiotherapy and CNS prophylaxis.
  • METHODS: In all, 37 patients with lymphoma involving the breast at initial diagnosis and managed at Stanford University from 1981-2005 were included.
  • Diagnostic tissue biopsies were obtained either from the breast mass or an involved lymph node.
  • Treatment and response data, patterns of recurrence, and outcomes were reviewed.
  • RESULTS: Diffuse large B cell lymphoma (DLBCL) was the most common histologic subtype seen in 18 of 37 (49%) patients.
  • Follicular and marginal zone subtypes were seen in 38%.
  • Most patients presented with an incidental breast mass in stage I(E) or II(E).
  • Four (11%) patients presented with bilateral breast involvement, with only 1 patient presenting with CNS disease.
  • DLBCL patients received doxorubicin-based chemotherapy, with 70% receiving involved field radiotherapy and a single patient receiving intrathecal therapy.
  • No recurrences occurred in the involved breast and a single parenchymal CNS recurrence was recorded.
  • Patients with indolent lymphoma had an estimated 5-year PFS of 76% and an OS of 92%.
  • CONCLUSIONS: DLBCL of the breast was successfully treated with doxorubicin-based chemotherapy alone or with involved field radiotherapy in an estimated 61% of patients at 5 years.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / analysis. Central Nervous System / pathology. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17541937.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 80168379AG / Doxorubicin
  •  go-up   go-down


3. Taeda Y, Ariga N, Okamura K, Takei N, Komeno T, Ueki H, Ohtani H: Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma with high-grade transformation evidenced by prominent lymphoepithelial lesions. Breast Cancer; 2006;13(3):322-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma with high-grade transformation evidenced by prominent lymphoepithelial lesions.
  • Primary breast lymphoma, particularly primary mucosa-associated lymphoid tissue (MALT) lymphoma, is a rare disease.
  • We report here a case of a MALT lymphoma of the breast with high-grade transformation.
  • An 84-year-old woman presented with a Pagetoid mass in her right breast.
  • After a clinical diagnosis of breast cancer, T2N1M0, stage II B, she underwent mastectomy with axillary lymph node dissection.
  • Pathologically the tumor tissue was composed of small to large lymphoid cells.
  • MALT lymphoma with high-grade transformation was diagnosed.
  • Rituximab (anti-CD20 antibody) was prescribed as systemic treatment without chemotherapy or irradiation.
  • We emphasize the importance of lymphoepithelial lesions for the diagnosis of MALT lymphoma of the breast.
  • [MeSH-major] Breast Neoplasms / complications. Cell Transformation, Neoplastic. Epithelial Cells / pathology. Lymphoid Tissue / pathology. Lymphoma, B-Cell, Marginal Zone / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Antineoplastic Agents / therapeutic use. Female. Humans. Lymphoma, B-Cell / pathology. Mastectomy. Rituximab

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929129.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


Advertisement
4. Liu MT, Hsieh CY, Wang AY, Pi CP, Chang TH, Huang CC, Huang CY: Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases. Ann Saudi Med; 2005 Jul-Aug;25(4):288-93
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast lymphoma: a pooled analysis of prognostic factors and survival in 93 cases.
  • BACKGROUND: Primary breast lymphoma is a rare disease.
  • We conducted a pooled analysis to evaluate the treatment outcome and prognostic factors in patients with primary breast lymphoma.
  • Treatments included single therapy or combined surgery, chemotherapy and radiotherapy.
  • We analyzed the correlation between treatment protocols, tumor relapse and survival.
  • Histopathology and cancer stage were analyzed to evaluate their significance in treatment outcome.
  • The histopathology of 63 patients (68%) was diffuse large cell lymphoma.
  • Thirteen percent received surgery alone, 27% received chemotherapy alone, 7% received radiotherapy alone, 10% received surgery and chemotherapy, 10% received surgery and radiotherapy, 22% received chemotherapy and radiotherapy, and 11% received surgery combined with chemotherapy and radiotherapy.
  • The mean time to first tumor relapse after treatment was 20 months.
  • Patients who received chemotherapy and radiotherapy had better survival outcome and a lower relapse rate.
  • We suggestthat chemotherapy and radiotherapy be the initial treatment for patients with primary breast lymphoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / therapy. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / epidemiology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16212120.001).
  • [ISSN] 0256-4947
  • [Journal-full-title] Annals of Saudi medicine
  • [ISO-abbreviation] Ann Saudi Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


5. Troch M, Jonak C, Müllauer L, Püspök A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M: A phase II study of bortezomib in patients with MALT lymphoma. Haematologica; 2009 May;94(5):738-42
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bortezomib in patients with MALT lymphoma.
  • We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma.
  • Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast.
  • Bortezomib appears to be active in patients with MALT-lymphoma.
  • [MeSH-major] Boronic Acids / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Pyrazines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Bortezomib. Diarrhea / chemically induced. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nausea / chemically induced. Nervous System Diseases / chemically induced. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Ann Oncol. 2007 Dec;18(12):2020-4 [17785766.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Gut. 2003 Nov;52(11):1656 [14570741.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1758-61 [14630681.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] Cancer. 2004 May 15;100(10):2190-4 [15139063.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1628-38 [1568573.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):607-12 [9681073.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7179-81 [15534090.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] Med Oncol. 2005;22(1):57-62 [15750197.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3136-41 [16769982.001]
  • [Cites] Ophthalmology. 2006 Jul;113(7):1209-13 [16647129.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1722-3 [16766585.001]
  • [Cites] Oncology. 2006;70(6):411-7 [17220639.001]
  • [Cites] Gut. 2007 Dec;56(12):1685-7 [17639089.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3872-7 [12228207.001]
  • (PMID = 19336742.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00373906
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Other-IDs] NLM/ PMC2675689
  •  go-up   go-down


6. Sancho JM, Ribera JM, Vaquero M, Oriol A, Hernández-Rivas JA, Feliu E: Non-gastrointestinal malt lymphomas: a study of 10 cases and comparison with 27 patients with gastrointestinal MALT lymphoma. Haematologica; 2000 May;85(5):557-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-gastrointestinal malt lymphomas: a study of 10 cases and comparison with 27 patients with gastrointestinal MALT lymphoma.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Chemical Analysis. Breast Neoplasms / drug therapy. Conjunctival Neoplasms / drug therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Gastrointestinal Neoplasms / drug therapy. Humans. Male. Middle Aged. Parotid Neoplasms. Prednisolone / administration & dosage. Prognosis. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10800182.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] ITALY
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


7. Giron GL, Hamlin PA, Brogi E, Mendez JE, Sclafani L: Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma. Am Surg; 2004 Aug;70(8):720-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the breast: a case of marginal zone B-cell lymphoma.
  • A case of primary marginal zone B-cell lymphoma in an elderly female patient is presented.
  • Primary breast lymphomas are rare, comprising less than 1 per cent of all breast malignancies.
  • These tumors have no clinical, pathologic, or radiologic pathognomonic features to distinguish them from breast adenocarcinoma.
  • The diagnosis is usually made with an excisional biopsy, and more extensive surgery should be avoided.
  • Delivery of radiation therapy and chemotherapy is tailored according to the histologic grade, stage of disease, and overall patient condition.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15328808.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Martinelli G, Ryan G, Seymour JF, Nassi L, Steffanoni S, Alietti A, Calabrese L, Pruneri G, Santoro L, Kuper-Hommel M, Tsang R, Zinzani PL, Taghian A, Zucca E, Cavalli F: Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Ann Oncol; 2009 Dec;20(12):1993-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.
  • BACKGROUND: Primary breast lymphoma (PBL) of low-grade histology is a rare disease.
  • PATIENTS AND METHODS: Patients with histologically proven, previously untreated follicular or marginal-zone PBL (MZL PBL) diagnosed from 1980 to 2003 were included in the study.
  • RESULTS: We collected data on 60 cases of PBL [36 follicular and 24 marginal-zone lymphoma (MZL)].
  • Stage was I(E) or II(E) in 57 patients and IVE in three patients due to bilateral breast involvement.
  • Surgery, chemotherapy and radiotherapy (RT), alone or in combination, were used as first-line treatments in 67%, 42% and 52% of patients, respectively.
  • Conversely, patients with follicular PBL had inferior PFS and OS when compared with limited-stage nodal follicular non-Hodgkin's lymphomas, suggesting an adverse prognostic role of primary breast localisation in this histological subgroup.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19570964.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Suzuki Y, Tokuda Y, Okumura A, Saito Y, Ohta M, Kubota M, Makuuchi H, Tajima T, Umemura S, Osamura RY: Three cases of malignant lymphoma of the breast. Jpn J Clin Oncol; 2000 Jan;30(1):33-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three cases of malignant lymphoma of the breast.
  • We report three cases of malignant lymphoma (ML) of the breast and discuss diagnosis and management.
  • The first case is a 35-year-old woman who had a left breast tumor.
  • Mastectomy was performed without any adjuvant chemotherapy.
  • Histology revealed diffuse large B-cell lymphoma of REAL classification.
  • She underwent eight cycles of CHOP regimen, but 1 month after the chemotherapy a brain metastasis was detected.
  • The second case is a 47-year-old woman who had anterior neck swelling and bilateral breast tumors.
  • Histology of the tumor revealed diffuse large B-cell lymphoma.
  • The patient underwent eight cycles of CHOP regimen and high-dose chemotherapy (HDC) with peripheral blood stem cell transplantation (PBSCT).
  • The third case is a 38-year-old woman who had a right breast tumor.
  • FNAC of the breast tumor showed ML and a CT scan of the chest revealed lymphadenopathy at the crus of the diaphragm.
  • Histology of the tumor revealed low-grade B-cell lymphoma of MALT type.
  • [MeSH-major] Breast Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Cranial Irradiation. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Lymphatic Metastasis / pathology. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Mastectomy, Extended Radical. Middle Aged. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10770567.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


10. Bilici A, Ozguroglu M, Tuzuner N, Goksel S, Turna H: Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case. Arch Gynecol Obstet; 2010 Nov;282(5):587-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case.
  • Primary breast lymphoma (PBL) is an uncommon type of extranodal non-Hodgkin's lymphoma (NHL), accounting for approximately 1% of all extranodal NHL.
  • Diffuse large B cell lymphoma (DLBCL) is the most frequent histology.
  • Both primary mucosa-associated lymphoid tissue (MALT) lymphoma of the breast and its relapse have been documented previously.
  • We report on a 63-year-old woman with primary DLBCL of the breast which was diagnosed 8 years after gastric MALT lymphoma.
  • Following chemotherapy, complete response was obtained.
  • We suggest that for women presenting with a breast mass who received cytotoxic treatment for the other lymphoma, PBL should be considered in the differential diagnosis of the breast mass together with primary breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419308.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


11. Guo HY, Zhao XM, Cao JN, Hu XC, Yin JL, Hong XN, Li J: [Prognosis of primary non-Hodgkin's lymphoma of the breast]. Zhonghua Zhong Liu Za Zhi; 2008 Mar;30(3):200-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of primary non-Hodgkin's lymphoma of the breast].
  • OBJECTIVE: To analyze the clinical characteristics and prognosis of primary non-Hodgkin's lymphoma of the breast (PNHLB).
  • METHODS: The characteristics, treatment methods and outcomes of 45 patients with PNHLB were retrospectively analyzed.
  • Chemotherapy including CHOP and CHOP-like regimens was administered in 43 patients, and monoclonal antibody therapy in 6 patients.
  • Furthermore, 19 patients underwent radiotherapy after chemotherapy.
  • RESULTS: Of these 45 patients, 37 patients had diffuse large B cell lymphoma (DLBCL), patients with T cell or mucosa-associated lymphoid tissue (MALT) lymphoma were 4, respectively.
  • Overall response rate of first-line chemotherapy was 90.7%.
  • Most pathologic type was DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal / therapeutic use. Breast Neoplasms, Male / drug therapy. Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / radiotherapy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, B-Cell, Marginal Zone / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18756936.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Park YH, Kim SH, Choi SJ, Ryoo BY, Kang YK, Lee SS: Primary malignant lymphoma of the breast: clinicopathological study of nine cases. Leuk Lymphoma; 2004 Feb;45(2):327-30
Genetic Alliance. consumer health - Primary malignant lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the breast: clinicopathological study of nine cases.
  • Primary lymphoma of the breast is rare, accounting for 1.7-2.2% of extranodal lymphomas and 0.38-0.7% of non-Hodgkin's lymphomas (NHL).
  • The aim of this study was to evaluate the clinicopathological features and treatment outcomes of patients with primary breast lymphomas (PBL).
  • All patients were women (median age, 45 years) and usually presented with breast masses that had recently become enlarged.
  • Six cases involved the breast alone (stage IE), whereas 3 cases also involved the ipsilateral axillary lymph nodes (stage IIE).
  • Histopathologic studies revealed a diffuse large B cell lymphoma in 7 cases, marginal zone B cell lymphoma in 1 case, and small lymphocytic lymphoma in 1 case.
  • Immunohistochemical analysis revealed a B-cell phenotype in all cases.
  • There was no uniform approach to the treatment of PBL.
  • Modified radical mastectomy and chemotherapy was performed in 4 cases, modified radical mastectomy and chemoradiotherapy was performed in 1 case, chemoradiotherapy alone, modified radical mastectomy alone, chemotherapy alone, and radiotherapy alone were performed in 1 case each.
  • All cases achieved complete remission, but median overall survival was 12 months, showing very poor prognosis irrespective of the type of treatment modality.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Neoplasms / pathology
  • [MeSH-minor] Adult. Breast. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101719.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Quilon JM, Gaskin TA, Ludwig AS, Alley C: Collision tumor: invasive ductal carcinoma in association with mucosa-associated lymphoid tissue (MALT) lymphoma in the same breast. South Med J; 2006 Feb;99(2):164-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor: invasive ductal carcinoma in association with mucosa-associated lymphoid tissue (MALT) lymphoma in the same breast.
  • Synchronous occurrence of multiple neoplastic processes is uncommon and the relationship between breast cancer with lymphoproliferative diseases is unusual as well.
  • Furthermore, breast involvement by malignant lymphoma is a rare event and primary breast mucosa-associated lymphoid tissue (MALT) lymphoma is even rarer.
  • We report a patient with synchronous occurrence of malignant lymphoma of MALT type and ductal carcinoma of the breast, presenting as "collision tumor," invading each other and occurring as a single mass in the breast.
  • Involvement of the sentinel lymph node by MALT lymphoma was demonstrated with no evidence of metastatic carcinoma.
  • Staging bone marrow biopsy did not show involvement by malignant lymphoma or carcinoma.
  • Our patient was treated with chemotherapy for the lymphoma.
  • She also received radiotherapy and aromatase inhibitor as adjuvant therapy for the breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Female. Humans. Mastectomy. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] South Med J. 2006 Feb;99(2):108-10 [16509544.001]
  • (PMID = 16509555.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Fruchart C, Denoux Y, Chasle J, Peny AM, Boute V, Ollivier JM, Genot JY, Michels JJ: High grade primary breast lymphoma: is it a different clinical entity? Breast Cancer Res Treat; 2005 Oct;93(3):191-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High grade primary breast lymphoma: is it a different clinical entity?
  • Primary lymphoma of the breast (PBL) is a rare neoplasm, its outcome remains unclear compared to other lymphomas.
  • There were 17 Diffuse large B cell lymphoma (DLBCL) and 2 follicular and diffuse grade 3 lymphomas.
  • Four patients were treated with local treatment only, 15 received chemotherapy including 11 treated with CHOP or ACVBP regimens followed by involved field radiotherapy.
  • Three of the 4 patients treated only with a local treatment died of their lymphoma.
  • Three patients progressed on therapy and 5 relapsed in the first year of follow-up including 2 central nervous system recurrences.
  • Among the 11 patients treated with chemotherapy, 2 died of their lymphoma.
  • The treatment should be based on the same modalities, but including a CNS prophylaxis even if poor prognosis factors are lacking.
  • A radical mastectomy increases the risk of treatment failure and has to be avoided.
  • [MeSH-major] Breast Neoplasms. Lymphoma, Follicular. Lymphoma, Large B-Cell, Diffuse
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. France / epidemiology. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / pathology. Middle Aged. Neprilysin / metabolism. Prognosis. Proto-Oncogene Proteins c-bcl-6 / metabolism. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172797.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


15. Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY: [Primary breast lymphoma--a report of 27 cases with literature review]. Ai Zheng; 2007 Jan;26(1):84-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast lymphoma--a report of 27 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary breast lymphoma (PBL) is an uncommon disease with poor clinical outcome.
  • This study was to investigate clinicopathologic features and optimal treatment of PBL.
  • RESULTS: Of the 27 patients, 26 were women and 1 was man, with the age ranged from 12 to 84; 18 were at stage IE, 6 at stage IIE, and 3 at stage III/IVE; according to the WHO 2001 lymphoma classification system, 22 had B-cell lymphoma (including 17 cases of diffuse large B-cell lymphoma, 2 cases of mucosa-associated lymphoid tissue lymphoma, 1 case of marginal zone lymphoma, and 2 cases of unclassified B-cell lymphoma), 3 had peripheral T-cell lymphoma, and 2 had unclassified lymphoma.
  • Of the 27 patients, 8 received mastectomy and chemotherapy, 12 received excision of the breast lesion and chemotherapy (the 5-year overall survival rates were 23% and 58%, P=0.006), 5 received chemotherapy alone, and 2 received lesion excision alone; 24 achieved complete remission (CR) after scheduled treatment, 1 achieved partial remission (PR), and 2 patients had progressive disease (PD).
  • As to the 20 patients with high or moderate grade diseases (diffuse large B-cell lymphoma and peripheral T-cell lymphoma), the 5-year overall and disease-free survival rates were 48% and 27%, respectively.
  • Sixteen patients had tumor relapse during the follow-up in the homolateral breast (6 cases), controlateral breast (4 cases), central nerve system (CNS) (3 cases), bone marrow (1 case), and lymph nodes (2 cases).
  • CONCLUSIONS: The main subtypes of PBL are diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms, Male / therapy. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Mastectomy / methods. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222374.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 14
  •  go-up   go-down


16. Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, Gaiger A, Turetschek K, Jaeger U, Streubel B, Zielinski CC: Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol; 2005 Nov 20;23(33):8442-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma.
  • PURPOSE: Various chemotherapeutic regimens have been applied for treatment of mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard regimen has been identified to date.
  • In view of the activity of oxaliplatin (L-OHP) in various types of lymphoma, we performed a phase II study to evaluate the activity of L-OHP for treatment of MALT lymphoma.
  • PATIENTS AND METHODS: A total of 16 patients with MALT lymphoma of various sites of origin (four of the ocular adnexa, five of the salivary glands, three of the stomach, two of the lung, and one of the colon and the breast) were administered L-OHP at a dose of 130 mg/m2 infused during 2 hours every 3 weeks.
  • Restaging was performed every two cycles; treatment was continued until complete remission (CR) or for a maximum of six cycles in responders.
  • Fifteen patients responded to chemotherapy, with nine achieving CR (56%), six (37.5%) achieving partial response, and one achieving stable disease; the median time to response was 4 months (range; 2 to 4 months).
  • CONCLUSION: These data suggest L-OHP is a highly active agent for treatment of MALT lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Organoplatinum Compounds / therapeutic use
  • [MeSH-minor] Adult. Aged. Austria / epidemiology. Female. Humans. Male. Middle Aged. Prospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293875.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin
  •  go-up   go-down


17. Kraemer DM, Weissinger F, Reimer P, Kunzmann V, Rüdiger T, Wilhelm M: Female patient with a history of Hashimoto's thyroiditis, diagnosed with MALT lymphoma of both breasts. Onkologie; 2003 Jun;26(3):277-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Female patient with a history of Hashimoto's thyroiditis, diagnosed with MALT lymphoma of both breasts.
  • BACKGROUND: Mucosa-associated lymphoid tissue (MALT) lymphomas are a distinct subgroup of non-Hodgkin's lymphomas with preferable localization in the gastrointestinal tract.
  • PATIENTS AND METHODS We describe the unusual case of a 48-year-old female patient, who was diagnosed with simultaneous MALT lymphoma of both breasts.
  • Cervical, axillary and retroperitoneal lymph nodes were slightly enlarged, indicating an infiltration by the lymphoma.
  • After 6 cycles of chemotherapy with CHOP regimen, the patient achieved complete remission.
  • CONCLUSION: To our knowledge, this is the first case describing a patient with MALT lymphoma of the breast and a history of Hashimoto's thyroiditis.
  • As patients suffering from autoimmune disorders, especially Sjögren's syndrome and Hashimoto's thyroiditis, are at a higher risk to develop B-cell lymphoma, we assume that Hashimoto's thyroiditis favored development of MALT lymphoma in our patient.
  • [MeSH-major] Autoimmune Diseases / complications. Breast Neoplasms / etiology. Lymphoma, B-Cell, Marginal Zone / etiology. Neoplasms, Multiple Primary / etiology. Thyroiditis, Autoimmune / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged. Prednisone / therapeutic use. Risk Factors. Treatment Outcome. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • (PMID = 12845214.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


18. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Crump M: Stage I and II MALT lymphoma: results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys; 2001 Aug 1;50(5):1258-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage I and II MALT lymphoma: results of treatment with radiotherapy.
  • PURPOSE: Mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct disease with specific clinical and pathologic features that may affect diverse organs.
  • We analyzed our recent experience with Stage I/II MALT lymphoma presenting in the stomach and other organs to assess the outcome following involved field radiation therapy (RT).
  • Presenting sites included stomach, 15; orbital adnexa, 19; salivary glands, 15; thyroid, 8; lung, 5; upper airways, 3 (nasopharynx, 2; larynx, 1); urinary bladder, 3; breast, 1; and rectum, 1.
  • Sixty-two patients received radiation therapy: 52 received RT alone, 7 received chemotherapy and RT, and 3 received antibiotics followed by RT.
  • Median RT dose was 30 Gy (range, 17.5--35 Gy).
  • Most frequently used RT prescriptions were 25 Gy (26 patients-18 orbit, 6 stomach, and 2 salivary glands), 30 Gy (23 patients), and 35 Gy (8 patients).
  • Five patients had complete surgical excision of lymphoma and no other treatment (stomach 1, salivary 2, lung 2), whereas 2 patients with gastric lymphoma received antibiotics only.
  • One patient refused treatment and was excluded from the analysis of treatment outcome, leaving 69 patients with a median follow-up of 4.2 years (range, 0.3-11.4 years).
  • No relapses were observed in patients with stomach and thyroid lymphoma.
  • Among 62 patients who received RT, 8 relapsed (2 salivary, 3 orbit, 1 nasopharynx, 1 larynx, 1 breast).
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy
  • [MeSH-minor] Adult. Aged. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chlorambucil / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prednisone / administration & dosage. Prognosis. Remission Induction. Retrospective Studies. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / surgery. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11483337.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; COP protocol 2
  •  go-up   go-down


19. Amouri A, Chtourou L, Mnif L, Mdhaffar M, Abid M, Ayedi L, Daoud J, Elloumi M, Boudawara T, Tahri N: [MALT lymphoma of the rectum: a case report treated by radiotherapy]. Cancer Radiother; 2009 Jan;13(1):61-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the rectum: a case report treated by radiotherapy].
  • [Transliterated title] Lymphome de MALT du rectum : à propos d'un cas traité par irradiation.
  • The mucosa-associated lymphoid tissue (MALT) lymphoma is a distinct clinical pathologic entity that develops in diverse anatomic locations such as the stomach, salivary gland, thyroid, lung, skin and breast.
  • To our knowledge, only ten cases of primary rectal MALT lymphoma have been reported in the literature.
  • We report a 46-year-old woman with rectal MALT lymphoma, which regressed after radiotherapy.
  • Microscopic and immunohistologic studies of the biopsy specimen showed typical features of low grade MALT lymphoma.
  • Upper endoscopy showed chronic gastritis with lymphoid follicles but without any infiltration of lymphoma cells.
  • No extra-intestinal involvement was found on the staging evaluation, which included computed tomography (CT) of the abdomen, chest, pelvis and a bone marrow biopsy.
  • Repeated colonoscopy 4 months after the end of treatment showed that the rectal tumor had not regressed.
  • Biopsy specimens confirmed the persistent infiltration of lymphoma cells.
  • The patient was considered to be a non-responder to eradication therapy and was indicated for radiotherapy.
  • He underwent a total of 34 Gy.
  • Complete regression was confirmed by colonoscopic and histologic examination at 2 months after the end of treatment.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / radiotherapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Biopsy. Chronic Disease. Colonoscopy. Female. Gastritis / complications. Gastritis / diagnosis. Gastritis / drug therapy. Gastrointestinal Hemorrhage / etiology. Helicobacter Infections / complications. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Patient Selection. Radiotherapy Dosage. Rare Diseases. Rectal Diseases / etiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19101191.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 27
  •  go-up   go-down


20. Michael CW, Richardson PH, Boudreaux CW: Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature. Ann Diagn Pathol; 2005 Jun;9(3):148-52
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
  • The diagnosis of lymphoma was suggested on bronchial brush smears.
  • A diagnosis of pulmonary lymphoma of the mucosa-associated lymphoid tissue type was established and the patient responded to chemotherapy treatment.
  • Over the following 5 years, she suffered at least 2 recurrences involving the lung and breast for which she received additional treatment.
  • [MeSH-major] Immunophenotyping. Lung Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Antigens, CD / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Chlorambucil / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15944957.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 18D0SL7309 / Chlorambucil; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Kuper-Hommel MJ, Snijder S, Janssen-Heijnen ML, Vrints LW, Kluin-Nelemans JC, Coebergh JW, Noordijk EM, Vreugdenhil G: Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews. Ann Hematol; 2003 Jul;82(7):397-404
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and survival of 38 female breast lymphomas: a population-based study with clinical and pathological reviews.
  • Breast lymphomas are rare and consensus about their treatment is lacking.
  • A population-based study of 38 breast lymphomas, registered in the databases of two Comprehensive Dutch Cancer Centers from 1981 to 1999, was performed.
  • The median age of all female patients was 65 years (20-92): 25 patients had localized and 13 patients had disseminated lymphoma.
  • The most common type was diffuse large B-cell lymphoma (DLBCL), which accounted for 17 of the localized and 4 of the disseminated cases.
  • Burkitt's lymphoma (BL), three being disseminated, was found in four patients.
  • There were six extranodal marginal zone lymphomas (ENMZL), three being localized.
  • Seven DLBCL and one BL showed additional histological features of mucosa-associated lymphoid tissue (MALT) lymphoma.
  • Localized aggressive lymphomas treated with surgery and/or radiation therapy had relapse rates of 100% and 67%, respectively.
  • Cyclophosphamide, hydroxydaunomycin, vincristine, and prednisone (CHOP)-like chemotherapy with or without local irradiation led to 17% relapses in patients with localized aggressive lymphoma.
  • Median follow-up time was 32 months (0.6-218); 37% of the patients relapsed and 24% had progressive disease.
  • The 2-year overall survival rate was 63%, 72% for patients with localized disease, and 46% for patients with disseminated lymphoma.
  • The majority of breast lymphomas are localized aggressive lymphomas that should be treated initially with CHOP-like chemotherapy with or without irradiation.
  • The initial choice of treatment is very important because response to salvage regimens is poor.
  • [MeSH-major] Breast Neoplasms / epidemiology. Lymphoma / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Classification. Combined Modality Therapy. Female. Humans. Incidence. Middle Aged. Netherlands / epidemiology. Recurrence. Remission Induction. Salvage Therapy. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12764549.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down






Advertisement